About the Authors
- Tomoko Yamashita
-
* E-mail: yamashita.tomoko@md.mt-pharma.co.jp
Affiliation Discovery Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan
- Yuki Miyamoto
-
Affiliation Department of Pharmacology, National Research Institute for Child Health and Development, Setagaya, Tokyo, Japan
- Yoshio Bando
-
Affiliation Department of Functional Anatomy and Neuroscience, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
- Takashi Ono
-
Affiliation Discovery Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan
- Sakurako Kobayashi
-
Affiliation Discovery Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan
- Ayano Doi
-
Affiliation Discovery Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan
- Toshihiro Araki
-
Affiliation Discovery Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan
- Yosuke Kato
-
Affiliation Discovery Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan
- Takayuki Shirakawa
-
Affiliation Discovery Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan
- Yutaka Suzuki
-
Affiliation Discovery Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan
- Junji Yamauchi
-
Affiliation Department of Pharmacology, National Research Institute for Child Health and Development, Setagaya, Tokyo, Japan
- Shigetaka Yoshida
-
Affiliation Department of Functional Anatomy and Neuroscience, Asahikawa Medical University, Asahikawa, Hokkaido, Japan
- Naoya Sato
-
Affiliations Discovery Research Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, MP Healthcare Venture Management, Boston, Massachusetts, United States of America
Competing Interests
TY, TO, SK, AD, TA, YK, TS, YS and NS are employed by Mitsubishi Tanabe Pharma Corporation. This study was also funded by Mitsubishi Tanabe Pharma Corporation. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: TY NS. Data curation: TY YM YB. Formal analysis: TY. Funding acquisition: NS. Investigation: TY YM YB TO SK AD TA YK TS YS. Methodology: TY YS NS. Project administration: NS. Supervision: NS. Validation: TY YM YB. Visualization: TY YM YB JY SY NS. Writing – original draft: TY. Writing – review & editing: TY JY SY NS.